## Understanding OTC Deficiency and Urea Cycle Pathophysiology ### The Correct Answer (Option 4 is WRONG) **Key Point:** In OTC deficiency, orotic acid excretion is **INCREASED**, not decreased. This is a high-yield distinguishing feature. ### Mechanism of Orotic Acid Elevation When ornithine transcarbamylase is deficient: 1. Carbamoyl phosphate accumulates in the mitochondrial matrix 2. Carbamoyl phosphate is shunted **INTO** the pyrimidine synthesis pathway (not away from it) 3. This leads to excessive production of orotic acid, which is excreted in large amounts in urine 4. Elevated urinary orotic acid is a diagnostic hallmark of OTC deficiency ### Why the Other Options Are Correct | Feature | Why Correct | |---------|-------------| | **X-linked inheritance, most common** | OTC is located on the X chromosome; accounts for ~50% of all urea cycle disorders [cite:Robbins 10e Ch 3] | | **CPS I activity increased** | Without OTC feedback inhibition, carbamoyl phosphate synthetase I continues to produce substrate, driving hyperammonemia | | **Elevated glutamine & alanine** | Ammonia is incorporated into glutamine (via glutamine synthetase); alanine rises due to transamination of pyruvate from amino acid catabolism | ### Clinical Pearl **Mnemonic: OROTATE UP in OTC** — Orotic acid is elevated in OTC deficiency, making urinary orotic acid a key diagnostic marker. This distinguishes OTC from other urea cycle defects (e.g., CPS I deficiency has normal orotic acid). ### High-Yield Distinction Orotic acid elevation is **specific to OTC deficiency** among urea cycle disorders because carbamoyl phosphate cannot proceed through the urea cycle and is diverted to pyrimidine synthesis.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.